Hematology ·
EBV DNA and Extranodal Disease Linked to PTLD-Specific Mortality
A retrospective study of 75 solid organ transplant recipients with post-transplant lymphoproliferative disorder (PTLD) used competing-risk analysis to assess disease-specific mortality. Detectable circulating EBV DNA and bone marrow or central nervous system involvement were independently associated with PTLD-related death.
- Study included 75 solid organ transplant recipients with PTLD.
- Twenty-five of 35 deaths were PTLD-related.
- Circulating EBV DNA was associated with PTLD-related mortality.
- Prospective validation in larger cohorts is needed.
Post-transplant lymphoproliferative disorder (PTLD) can arise in solid organ transplant recipients receiving immunosuppression, and deaths may also occur from causes unrelated to PTLD. Researchers retrospectively analysed 75 recipients with PTLD using Fine–Gray competing-risk regression to identify factors associated with PTLD-related mortality. Median follow-up was 71 months.
Thirty-five patients (46.7%) died; 25 of those deaths (71.4%) were attributed to PTLD. After adjustment for the International Prognostic Index, bone marrow or central nervous system involvement was associated with PTLD-related mortality (subdistribution hazard ratio [sHR], 3.82; 95% CI, 1.67–8.73; p=0.001). Detectable circulating Epstein–Barr virus (EBV) DNA was also associated with mortality (sHR, 4.38; 95% CI, 1.63–11.76; p=0.003). Combined tissue and blood EBV status showed a graded mortality pattern across four subgroups, from dual-positive to dual-negative.
The findings suggest that disease site and circulating EBV DNA may add prognostic information beyond IPI in this cohort. The retrospective analysis is small, and the authors call for prospective validation in larger multicentre cohorts; these associations do not establish that changing management based on the markers improves outcomes.
In practice
In solid organ transplant recipients with PTLD, detectable circulating EBV DNA and bone marrow or central nervous system involvement were associated with PTLD-related mortality independently of the International Prognostic Index in this retrospective cohort. These findings may inform prognostic assessment, but they do not show that marker-guided treatment or monitoring improves outcomes. The cohort included only 75 patients, and the authors call for prospective validation in larger multicentre studies; the results should not be treated as a validated risk tool.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
British Journal of Haematology: Circulating Epstein–Barr virus DNA and high‐risk extra‐nodal involvement identify disease‐specific mortality in post‐transplant lymphoproliferative disorder ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.